Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN012
MIFTS: 42

Adenocarcinoma in Situ

Categories: Cancer diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Adenocarcinoma in Situ

About this section

MalaCards integrated aliases for Adenocarcinoma in Situ:

Name: Adenocarcinoma in Situ 12 45 15 74

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4943
MeSH 45 D065311
NCIt 51 C4123
SNOMED-CT 69 51642000
UMLS 74 C0334276
Sources

Summaries for Adenocarcinoma in Situ

About this section
Disease Ontology : 12 An in situ carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Adenocarcinoma in Situ is related to cervical adenocarcinoma and appendix adenocarcinoma. An important gene associated with Adenocarcinoma in Situ is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Primary Focal Segmental Glomerulosclerosis FSGS. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and testes, and related phenotypes are cellular and embryo

Sources

Related Diseases for Adenocarcinoma in Situ

About this section

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 201)
# Related Disease Score Top Affiliating Genes
1 cervical adenocarcinoma 30.9 CDKN2A CDX2 KRT20 KRT7
2 appendix adenocarcinoma 30.2 CDX2 KRT20 KRT7
3 endometrial adenocarcinoma 30.1 CDKN2A KRAS KRT7
4 large cell neuroendocrine carcinoma 30.1 KRT20 KRT7
5 lung cancer susceptibility 3 30.1 CDKN2A CDX2 KRAS KRT20 KRT7
6 endometrial mucinous adenocarcinoma 30.0 CDKN2A PAX2
7 endocervical adenocarcinoma 29.9 CDKN2A CDX2 KRT20 KRT7 PAX2 PAX8
8 villous adenoma 29.8 CDX2 KRAS KRT20
9 cystic teratoma 29.8 CDX2 KRT20 KRT7
10 papillary carcinoma 29.8 KRT20 KRT7 PAX8
11 mucinous adenocarcinoma 29.7 CDKN2A CDX2 KRAS KRT20 KRT7
12 pseudomyxoma peritonei 29.6 CDX2 KRAS KRT20 KRT7
13 bronchiolo-alveolar adenocarcinoma 29.6 CDX2 KRAS KRT20 KRT7
14 colorectal adenocarcinoma 29.6 CDX2 KRAS KRT20 KRT7
15 barrett esophagus 29.5 CDKN2A CDX2 KRT20 KRT7
16 endometrial cancer 29.1 CDKN2A KRAS KRT7 MUC16 PAX8
17 in situ pulmonary adenocarcinoma 11.3
18 early invasive cervical adenocarcinoma 11.1
19 adenocarcinoma 10.9
20 vulva cancer 10.4 CDKN2A KRT7
21 tonsil cancer 10.4 CDKN2A KRT7
22 gastric tubular adenocarcinoma 10.4 CDX2 KRT7
23 hidradenocarcinoma 10.4 CDX2 KRT7
24 inverted transitional papilloma 10.4 CDKN2A KRT7
25 mammary paget's disease 10.4 KRT20 KRT7
26 tubular adenocarcinoma 10.4 CDX2 KRT20
27 ovary neuroendocrine neoplasm 10.4 CDX2 KRT7
28 mucinous adenofibroma 10.4 CDX2 KRT7
29 anus adenocarcinoma 10.4 CDX2 KRT7
30 adenoid basal cell carcinoma 10.4 CDKN2A KRT7
31 bladder carcinoma in situ 10.4 CDKN2A KRT7
32 vulvar disease 10.3 CDKN2A KRT7
33 deafness, autosomal dominant 10 10.3 PAX2 PAX8
34 retinal hemangioblastoma 10.3 PAX2 PAX8
35 cystic basal cell carcinoma 10.3 KRT20 KRT7
36 renal pelvis adenocarcinoma 10.3 KRT7 PAX8
37 seminal vesicle adenocarcinoma 10.3 KRT20 KRT7
38 transverse colon cancer 10.3 KRT20 KRT7
39 malignant syringoma 10.3 KRT20 KRT7
40 anal canal carcinoma 10.3 CDKN2A KRT7
41 sensory organ benign neoplasm 10.3 KRT7 PAX8
42 vaginal benign neoplasm 10.3 CDX2 KRT20
43 vaginal adenoma 10.3 CDX2 KRT20
44 vaginal tubulovillous adenoma 10.3 CDX2 KRT20
45 papillary transitional carcinoma 10.3 KRT20 KRT7
46 eyelid carcinoma 10.3 KRT20 KRT7
47 krukenberg carcinoma 10.3 KRT20 KRT7
48 large intestine adenocarcinoma 10.3 KRT20 KRT7
49 core binding factor acute myeloid leukemia 10.3 KRAS WT1
50 linitis plastica 10.3 KRT20 KRT7

Graphical network of the top 20 diseases related to Adenocarcinoma in Situ:



Diseases related to Adenocarcinoma in Situ
Sources

Symptoms & Phenotypes for Adenocarcinoma in Situ

About this section

MGI Mouse Phenotypes related to Adenocarcinoma in Situ:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.56 CDKN2A CDX2 GGN KRAS KRT7 PAX2
2 embryo MP:0005380 9.1 CDKN2A CDX2 KRAS PAX2 PAX8 WT1
Sources

Drugs & Therapeutics for Adenocarcinoma in Situ

About this section

Drugs for Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
2 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2
3
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
4 Immunoglobulins Phase 3,Phase 2
5 Antibodies Phase 3,Phase 2
6 Anti-Ulcer Agents Phase 3
7 Antacids Phase 3
8 Adjuvants, Immunologic Phase 3
9 Gastrointestinal Agents Phase 3
10
Testosterone Approved, Experimental, Investigational Phase 1, Phase 2 58-22-0, 481-30-1 10204 6013
11
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1, 83869-56-1
12
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
13
Ipilimumab Approved Phase 2 477202-00-9
14
nivolumab Approved Phase 2 946414-94-4
15
Metformin Approved Phase 2 657-24-9 14219 4091
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1, Phase 2
17 Immunosuppressive Agents Phase 1, Phase 2
18 Alkylating Agents Phase 1, Phase 2
19 Hormone Antagonists Phase 1, Phase 2
20 Antirheumatic Agents Phase 1, Phase 2
21 Hormones Phase 1, Phase 2
22 Androgens Phase 1, Phase 2
23 Antineoplastic Agents, Alkylating Phase 1, Phase 2
24 Antineoplastic Agents, Immunological Phase 2
25 Antibodies, Monoclonal Phase 2
26 Hypoglycemic Agents Phase 2
27
Proflavine Approved Not Applicable 92-62-6 7099
28 Anti-Infective Agents, Local Not Applicable
29 Anti-Infective Agents Not Applicable
30 Pharmaceutical Solutions Not Applicable

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
2 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
3 Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO) Unknown status NCT01429649 Phase 3
4 Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants Completed NCT00128661 Phase 3
5 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
6 Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041) Completed NCT00834106 Phase 3
7 Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects Completed NCT00779766 Phase 3
8 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 Completed NCT00122681 Phase 3
9 Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study Completed NCT00929526 Phase 3
10 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older Completed NCT00294047 Phase 3
11 Safety and Immunogenicity Study of V503 (GARDASILâ„¢9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
12 Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women Completed NCT01461096 Phase 3
13 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
14 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
15 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
16 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213) Active, not recruiting NCT03493542 Phase 3
17 Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3
18 A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer Completed NCT01696877 Phase 1, Phase 2 degarelix acetate;Cyclophosphamide;GVAX
19 Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) Completed NCT00365716 Phase 2
20 V501 Efficacy Study in Women Aged 18 to 26 (V501-027) Completed NCT00378560 Phase 2
21 Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil Completed NCT00518336 Phase 2
22 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
23 Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer Active, not recruiting NCT03053544 Phase 2 Metformin
24 Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease Completed NCT00709891 Not Applicable
25 Randomized Controlled Trial of Human Papillomavirus Testing in Primary Cervical Cancer Screening Completed NCT00479375 Not Applicable
26 Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study Completed NCT02323997
27 In the Era of the HPV Vaccine, What Are The Current HPV Subtypes Contributing to High Grade Cervical Dysplasia, Adenocarcinoma in Situ, and Early Cervical Cancer? Recruiting NCT02937155
28 Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021 Not Applicable
29 Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix Active, not recruiting NCT02206048 Not Applicable Proflavine
30 Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) Active, not recruiting NCT02653118
31 A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects Active, not recruiting NCT03438006
32 Treatment of Multifocal Lung Adenocarcinoma Active, not recruiting NCT01946100 Not Applicable
33 Evaluation of Long-term HPV Vaccine Efficacy Enrolling by invitation NCT01393470
34 A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing Enrolling by invitation NCT02705404
35 Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer Suspended NCT02574442

Search NIH Clinical Center for Adenocarcinoma in Situ

Cochrane evidence based reviews: adenocarcinoma in situ

Sources

Genetic Tests for Adenocarcinoma in Situ

About this section
Sources

Anatomical Context for Adenocarcinoma in Situ

About this section

MalaCards organs/tissues related to Adenocarcinoma in Situ:

42
Cervix, Lung, Testes, Colon, Ovary, Breast, Appendix
Sources

Publications for Adenocarcinoma in Situ

About this section

Articles related to Adenocarcinoma in Situ:

(show top 50) (show all 292)
# Title Authors Year
1
Challenges in the Pap diagnosis of endocervical adenocarcinoma in situ. ( 31097290 )
2019
2
Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015. ( 30980692 )
2019
3
Histogram analysis combined with morphological characteristics to discriminate adenocarcinoma in situ or minimally invasive adenocarcinoma from invasive adenocarcinoma appearing as pure ground-glass nodule. ( 30927953 )
2019
4
Cervical Screening Results Leading to Detection of Adenocarcinoma in Situ of the Uterine Cervix ( 30803195 )
2019
5
Distinctive clinicopathological features of adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung: A retrospective study. ( 30797486 )
2019
6
A case study of gastric-type adenocarcinoma in situ of the uterine cervix. ( 30417947 )
2019
7
RANZCOG Fellows' adherence to guidelines following cytological prediction of cervical adenocarcinoma-in-situ: Cause for concern? ( 30284744 )
2019
8
Endocervical Adenocarcinoma In Situ Phenotype with Ovarian Metastasis. ( 30599504 )
2018
9
Genomic analyses based on pulmonary adenocarcinoma in situ reveal early lung cancer signature. ( 30453959 )
2018
10
Atypical carcinoid of the uterine cervix accompanying adenocarcinoma in situ. ( 30154130 )
2018
11
Strategy of intentional limited resection for lung adenocarcinoma in situ. ( 30023107 )
2018
12
Anal gland adenocarcinoma in situ with pagetoid spread: a case report. ( 29943205 )
2018
13
Is a 5-mm diameter an appropriate cut-off value for the diagnosis of atypical adenomatous hyperplasia and adenocarcinoma in situ on chest computed tomography and pathological examination? ( 29780625 )
2018
14
Risk of persistent or recurrent cervical neoplasia in patients with 'pure' adenocarcinoma-in-situ (AIS) or mixed AIS and high-grade cervical squamous neoplasia (cervical intra-epithelial neoplasia grades 2 and 3 (CIN 2/3)): a population-based study. ( 28678394 )
2018
15
HRCT texture analysis for pure or part-solid ground-glass nodules: distinguishability of adenocarcinoma in situ or minimally invasive adenocarcinoma from invasive adenocarcinoma. ( 29273964 )
2018
16
A case of urachal villous adenoma with high grade dysplasia focally bordering on adenocarcinoma in situ. ( 29321972 )
2018
17
Adenocarcinoma in situ admixed with small cell neuroendocrine carcinoma of the cervix: A case report with cytological features. ( 29656585 )
2018
18
Coexistence of Cervical Leiomyosarcoma and Gastric-Type Adenocarcinoma In Situ with Extensive Extension to the Endometrium and Fallopian Tube. ( 29670794 )
2018
19
Oncological and reproductive outcomes of adenocarcinoma in situ of the cervix managed with the loop electrosurgical excision procedure. ( 29690868 )
2018
20
Case of anal adenocarcinoma in situ with pagetoid spread but without macroscopic abnormality in anal mucosa. ( 27666572 )
2017
21
Risk of persistent and recurrent cervical neoplasia following incidentally detected adenocarcinoma in situ. ( 27908632 )
2017
22
Comparison of Cold-Knife Conization versus Loop Electrosurgical Excision for Cervical Adenocarcinoma In Situ (ACIS): A Systematic Review and Meta-Analysis. ( 28125627 )
2017
23
Cutaneous papillary adenocarcinoma in situ. ( 28164358 )
2017
24
Risk of persistent or recurrent neoplasia in conservatively treated women with cervical adenocarcinoma in situ with negative histological margins. ( 28181670 )
2017
25
Response to: Cutaneous papillary adenocarcinoma in situ. ( 28299799 )
2017
26
False-Negative Interpretation of Adenocarcinoma In Situ in the College of American Pathologists Gynecologic PAP Education Program. ( 28301226 )
2017
27
HPV-negative Gastric Type Adenocarcinoma In Situ of the Cervix: A Spectrum of Rare Lesions Exhibiting Gastric and Intestinal Differentiation. ( 28394803 )
2017
28
Two cases of adenocarcinoma in situ arising in lobular endocervical glandular hyperplasia indicating localization of mucin on the cluster surface as an early cytological finding of malignant transformation. ( 28449203 )
2017
29
Adenocarcinoma In Situ Arising from Brunner's Gland Treated by Endoscopic Mucosal Resection. ( 28512587 )
2017
30
Targeted next-generation sequencing for analyzing the genetic alterations in atypical adenomatous hyperplasia and adenocarcinoma in situ. ( 28821955 )
2017
31
Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. ( 28851799 )
2017
32
Human Papillomavirus-Associated Adenocarcinoma In Situ of the Vestibule. ( 28953132 )
2017
33
Solitary pulmonary capillary hemangioma presents as ground glass opacity on computed tomography indicating adenocarcinoma in situ/atypical adenomatous hyperplasia: A case report. ( 29188054 )
2017
34
Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma in situ and minimally invasive adenocarcinoma of lung. ( 29228652 )
2017
35
Mini-laparoscopic hysterectomy for adenocarcinoma in situ of the uterine cervix using interchangeable 5-mm end effectors: a way to cross the line of minimally invasive surgery in gynaecologic oncology. ( 29479402 )
2017
36
Adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive pulmonary adenocarcinoma--analysis of interobserver agreement, survival, radiographic characteristics, and gross pathology in 296 nodules. ( 27067781 )
2016
37
Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. ( 27137345 )
2016
38
Pattern-based classification of invasive endocervical adenocarcinoma, depth of invasion measurement and distinction from adenocarcinoma in situ: interobserver variation among gynecologic pathologists. ( 27174588 )
2016
39
Diagnosis of lung adenocarcinoma in situ and minimally invasive adenocarcinoma from intraoperative frozen sections: an analysis of 136 cases. ( 27174927 )
2016
40
Gastric-type adenocarcinoma in situ of uterine cervix: cytological and histopathological features of two cases. ( 27334141 )
2016
41
Syringocystadenocarcinoma Papilliferum In Situ, a Variant of Cutaneous Adenocarcinoma In Situ: A Case Report With Literature Review. ( 27533073 )
2016
42
Epidermal growth factor receptor mutations in adenocarcinoma in situ and minimally invasive adenocarcinoma detected using mutation-specific monoclonal antibodies. ( 27565930 )
2016
43
Microenvironmental changes in the progression from adenocarcinoma in situ to minimally invasive adenocarcinoma and invasive lepidic predominant adenocarcinoma of the lung. ( 27597281 )
2016
44
Thin-section computed tomography-histopathologic comparisons of pulmonary focal interstitial fibrosis, atypical adenomatous hyperplasia, adenocarcinoma in situ, and minimally invasive adenocarcinoma with pure ground-glass opacity. ( 27666606 )
2016
45
Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. ( 25987897 )
2015
46
Coexistence of mature cystic teratoma and adenocarcinoma in situ within atypical proliferative mucinous tumour of ovary--a case report of 35-year-old woman. ( 26050362 )
2015
47
Secondhand Tobacco Smoke Exposure and Lung Adenocarcinoma In Situ/Minimally Invasive Adenocarcinoma (AIS/MIA). ( 26503035 )
2015
48
Prognosis and status of lymph node involvement in patients with adenocarcinoma in situ and minimally invasive adenocarcinoma-a systematic literature review and pooled-data analysis. ( 26716039 )
2015
49
Laparoscopic Oophorectomy and Radical Lymph Node Dissection for a Recurrent Adenocarcinoma In Situ of the Cervix. ( 27678792 )
2015
50
Extrafascial Hysterectomy Without Preoperative Conization is Unacceptable in Patients With Adenocarcinoma in Situ Diagnosed by Cervical Punch Biopsy or Endocervical Curettage. ( 27679125 )
2015
Sources

Variations for Adenocarcinoma in Situ

About this section
Sources

Expression for Adenocarcinoma in Situ

About this section
Search GEO for disease gene expression data for Adenocarcinoma in Situ.
Sources

Pathways for Adenocarcinoma in Situ

About this section

Pathways related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.46 CDX2 PAX2 WT1
2
Primary Focal Segmental Glomerulosclerosis FSGS 1
10.67 CLDN1 PAX2 WT1
3
ID signaling pathway 1
10.16 PAX2 PAX8
Sources

GO Terms for Adenocarcinoma in Situ

About this section

Biological processes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.96 CDKN2A CDX2 PAX2 PAX8 WT1
2 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.61 PAX2 PAX8
3 positive regulation of cellular senescence GO:2000774 9.61 CDKN2A KRAS
4 branching involved in ureteric bud morphogenesis GO:0001658 9.61 PAX2 PAX8 WT1
5 urogenital system development GO:0001655 9.6 PAX2 PAX8
6 mesonephros development GO:0001823 9.59 PAX2 PAX8
7 mesenchymal to epithelial transition GO:0060231 9.58 PAX2 WT1
8 cellular response to gonadotropin stimulus GO:0071371 9.58 PAX8 WT1
9 metanephric mesenchyme development GO:0072075 9.57 PAX2 WT1
10 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.55 PAX2 PAX8
11 pronephros development GO:0048793 9.54 PAX2 PAX8
12 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.52 PAX2 PAX8
13 metanephric S-shaped body morphogenesis GO:0072284 9.51 PAX8 WT1
14 metanephric distal convoluted tubule development GO:0072221 9.49 PAX2 PAX8
15 metanephric nephron tubule formation GO:0072289 9.48 PAX2 PAX8
16 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.46 PAX2 PAX8
17 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.4 PAX2 PAX8
18 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.37 PAX2 PAX8
19 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.32 PAX2 PAX8
20 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.26 PAX2 PAX8
21 positive regulation of metanephric DCT cell differentiation GO:2000594 9.16 PAX2 PAX8
22 pronephric field specification GO:0039003 8.96 PAX2 PAX8
23 metanephric epithelium development GO:0072207 8.8 PAX2 PAX8 WT1
24 positive regulation of transcription by RNA polymerase II GO:0045944 10.02 CDKN2A PAX2 PAX8 TOP2A WT1
Sources

Sources for Adenocarcinoma in Situ

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....